Atrial fibrillation and dabigatran: Has the time come to use new anticoagulants?

Cardiovascular Therapeutics

Volumn 28, Issue 5, 2010, Pages 295-301

  Escobar, Carlos ^a   Barrios, Vivencio ^b   Jimenez, David ^b  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Anticoagulation; Arrhythmias; Coagulation Thrombosis; Dabigatran

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MECHANISM; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; HEMORRHAGE; HUMANS; RISK ASSESSMENT; THROMBIN; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 77956440922     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00216.x     Document Type: Review

References (33)

1. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 114 : e257 e354.
2. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003 14 : 666 672.
3. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: Implications for primary prevention. Circulation 2003 108 : 711 716.
4. Le Heuzey JY, Paziaud O, Piot O, Said MA, Copie X, Lavergne T, Guize L. Cost of care distribution in atrial fibrillation patients: The COCAF study. Am Heart J 2004 147 : 121 126.
5. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart 2004 90 : 286 292.
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001 285 : 2370 2375.
7. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994 74 : 236 241.
8. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995 98 : 476 484.
9. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002 113 : 359 364.
10. [No authors listed]. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 154 : 1449 1457.
11. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med 1999 131 : 688 695.
12. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999 131 : 492 501.
13. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004 110 (Suppl I I19 I26.
14. Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I. Pharmacokinetics and pharmacodynamics of new oral anticoagulants. Farm Hosp 2009 33 : 125 133.
15. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008 47 : 285 295. (Pubitemid 351508116)
16. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): A randomised controlled trial. Lancet 2006 367 : 1903 1912.
17. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 2005 105 : 453 463.
18. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, Turibio FM from the Global Orthopaedic Registry). Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events. J Bone Joint Surg Br 2007 89-B : 799 807.
19. Bates SM, Weitz JI. New anticoagulants beyond heparin, low molecular-weight heparin and warfarin. Br J Pharmacol 2005 144 : 1017 1028.
20. Baetz BE, Spinler SA. Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008 28 : 1354 1373.
21. European Medicines Agency (EMEA). Pradaxa H-C-829. Updated 15-Dec-2009. Available from : http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829- en6.pdf Accessed 11 May 2010 MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis. 2010 29 : 29 104.
22. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008 36 : 386 399. (Pubitemid 351185753)
23. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 64 : 292 303.
24. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost 2007 5 : 2178 2185. (Pubitemid 47617868)
25. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet 2007 370 : 949 956. (Pubitemid 47393577)
26. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009 24 : 1 9.
27. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009 101 : 77 85.
28. Fuji T, Fuijita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients, with a safety profile comparable to placebo. J Arthroplasty 2009. doi :.
29. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009 31 : 194 212.
30. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009 361 : 2342 2352.
31. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009 157 : 805 810.
32. Camm AJ. The RE-LY study: Randomized evaluation of long-term anticoagulant therapy: Dabigatran vs. warfarin. Eur Heart J 2009 30 : 2554 2555.
33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 361 : 1139 1151.